Opus Genetics (IRD) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Opus Genetics (IRD) has outperformed Turn Therapeutics (TTRX) over the past year, gaining 117.2% versus a gain of 72.9%. Opus Genetics is the larger company by market cap ($371.1 million vs $345.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | TTRX |
|---|---|---|
| Share price | $4.46 | $11.39 |
| Market cap | $371.05M | $345.89M |
| 1-day change | +1.13% | -5.87% |
| YTD return | +119.40% | +207.11% |
| 1-year return | +117.24% | +72.86% |
| 5-year return | +2.80% | — |
| EPS (TTM) | $-1.27 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.07 | $26.50 |
| 52-week low | $1.70 | $2.57 |
| Distance from 52-week high | -36.92% | -57.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +200.67% | +119.49% |
| Average volume | 2.37M | 111.72K |
| Shares outstanding | 83.20M | 30.37M |
| Employees | 27 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed TTRX by 44.4 percentage points over the past year.
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
IRD vs TTRX FAQ
Which is bigger, Opus Genetics or Turn Therapeutics?
Opus Genetics (IRD) is larger, with a market capitalization of $371.05M compared with $345.89M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, IRD or TTRX?
IRD returned +117.24% over the past 12 months, compared with +72.86% for TTRX (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.